Titan Medical Announces Addition of Deepak Basra as Vice President, Strategy and Business Development

Monday, 24. May 2021 13:30

TORONTO, May 24, 2021 (GLOBE NEWSWIRE) -- Titan Medical Inc. (Nasdaq: TMDI; TSX: TMD), a medical device company focused on the design and development of surgical technologies for robotic single access surgery, today announced the addition of Deepak Basra as Vice President, Strategy and Business Development to the leadership team. In this newly created role, Mr. Basra will oversee Titan’s corporate development and strategic planning.

"We are thrilled to welcome Deepak to Titan. His wealth of knowledge and experience in business development and strategic partnerships will be instrumental in growing Titan,” said David McNally, President and Chief Executive Officer of Titan. “We look forward to Deepak’s contributions as we execute on our vision of advancing our Enos™ robotic single access surgery system.”

Mr. Basra joins Titan with over 20 years’ experience in global business development and mergers and acquisitions (M&A). Most recently, he served as Senior Vice President with Cortland Advisers, LLC, an international M&A advisory firm. His corporate experience includes serving as Board Director and Vice President, Strategy and Business development for Transdermal Delivery Solutions Corporation (TDSC). Prior to TDSC, he was Head of Business Development and Licensing for Covidien’s vascular therapies division. He also served as Senior Vice President, Strategy and Business Development at Smith & Nephew prior to Covidien. Earlier, Mr. Basra held various business development, M&A and alliance management roles of increasing responsibility at Cable & Wireless, British Telecommunications PLC, and at Phillips in the telecommunications division. Mr. Basra holds a Bachelor of Science from Edinburgh University, a Post-Graduate Diploma in International Marketing from Buckinghamshire College, UK, and a Master of Business Administration from Henley Management College, UK.

About Titan Medical Inc.

Titan Medical Inc. is a medical device company headquartered in Toronto, Ontario and with R&D facilities in Chapel Hill, North Carolina, is focused on enhancing robotic assisted surgery using innovative technology through a single access point. The Enos™ robotic single access surgical system is being developed with an ergonomic focus to provide a surgical experience that imitates real-life movements that surgeons demand, and includes multi-articulating instruments designed to allow surgeons an increased range of motion in a confined space, with dexterity and the ability to exert the forces necessary to complete common surgical tasks. With the Enos system, Titan intends to initially pursue gynecologic surgical indications. Certain of Titan’s robotic assisted surgical technologies and related intellectual property have been licensed to Medtronic plc, while retaining world-wide rights to commercialize the technologies for use with the Enos system.

Enos™ is a trademark of Titan Medical Inc.

For more information, visit www.titanmedicalinc.com.

Forward-Looking Statements

This news release contains “forward-looking statements” within the meaning of applicable Canadian and U.S. securities laws, which reflect the current expectations of management of the Company’s future growth, results of operations, performance, and business prospects and opportunities. Wherever possible, words such as “may”, “would”, “could”, “will”, “anticipate”, “believe”, “plan”, “expect”, “intend”, “estimate”, “potential for” and similar expressions have been used to identify these forward-looking statements, including, without limitation, references to: the Company’s focus on the design and development of surgical technologies for robotic single access surgery, the Enos system is being developed with dual 3D and 2D high-definition vision systems, multi-articulating instruments and an ergonomic surgeon workstation, and that Titan intends to initially pursue gynecologic surgical indications. These statements reflect management’s current beliefs, and are based on information currently available to management. Forward-looking statements involve significant risks, uncertainties and assumptions. Many factors could cause the Company’s actual results, performance or achievements to be materially different from any future results, performance or achievements that may be expressed or implied by such forward-looking statements, including, without limitation, those listed in the “Risk Factors” section of the Company’s Annual Information Form and Form 40-F for the fiscal year ended December 31, 2020 (which may be viewed at www.sedar.com and at www.sec.gov). Should one or more of these risks or uncertainties materialize, or should assumptions underlying the forward-looking statements prove incorrect, actual results, performance, or achievements may vary materially from those expressed or implied by the forward-looking statements contained in this news release. These factors should be considered carefully, and prospective investors should not place undue reliance on the forward-looking statements. Although the forward-looking statements contained in the news release are based upon what management currently believes to be reasonable assumptions, the Company cannot assure prospective investors that actual results, performance or achievements will be consistent with these forward-looking statements. Except as required by law, the Company expressly disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise.

Contact
Kristen Galfetti
Vice President, Investor Relations       
& Corporate Communications
+1-781-869-2553
investors@titanmedicalinc.com


Related Links: 
Author:
Copyright GlobeNewswire, Inc. 2016. All rights reserved.
You can register yourself on the website to receive press releases directly via e-mail to your own e-mail account.